Rapid CAR T manufacturing is about more than speed

New manufacturing systems are set to change the way CAR T cells are delivered to patients in the near term, regardless of how well the technologies can deliver on their original promise of shaving weeks off patient wait times.

Accelerating the process is the primary goal of the next-generation manufacturing platforms for autologous CAR T cell therapies, but other benefits are becoming apparent as early clinical data begin to trickle in — and those benefits stand on their own...